-
Nepal floods leave trail of destruction, aid challenge
-
Kinshasa urban train back on track after years to beat gridlock
-
Experts outline sustainable ways to declutter Australian homes
-
Merino crossbreeding plan tests Himachal Pradesh wool ambitions
-
Bulk book purchases feed AI training through destructive scanning
-
Pringles launches thicker Dippers range for US snack market
-
George and Amal Clooney attend Lake Como event after France evacuation
-
US and Venezuela announce 65-billion-barrel oil development agreement
-
Michelle Obama describes relief and adjustment after daughters leave home
-
Assistance-dog dispute puts Great Bernera community groups under financial strain
-
Very strong El Niño forecast to peak during southern African summer
-
Sello Hatang remembers actor Sol Rachilo through a personal archive
-
SAFA opens tender for dressing rooms, ablutions and grandstands
-
UN committee calls on South Africa to dismantle racist vigilante groups
-
TEEKS brings Māori-rooted soul and a new view of masculinity to South Africa
-
South African creators seek stronger businesses beyond brand partnerships
-
Saudi customs seize 1.95 million amphetamine pills in lentil shipment
-
Syria warns Israeli actions could push region toward wider war
-
Trump says Russia will not attack NATO as CIA chief visits Moscow
-
East Midlands Railway warns of bank holiday disruption at St Pancras
-
British Museum schedules new Bayeux Tapestry ticket release
-
Six treated after sign falls at Big Church Festival in West Sussex
-
From forced labour to living heritage: Sao Tome's colonial plantations
-
Norway, in mourning, enters a new era under Haakon VIII
-
Motorola September 2026 Deals: Up to $700 Off Razr Ultra and Moto G
-
Number of missing in Nepal, China floods soars to nearly 3,000
-
In war-split Myanmar 'spirit consorts' commune across divide
-
Number of missing in Nepal, China floods soars past 2,400
-
Leaders of Russia, China, Iran to attend summit in Kyrgyzstan
-
Trump announces deal for huge US stake in Venezuelan oil reserves
-
Alpha1 AI Expands Support for Federal Agencies
-
Hovland and Gerard share lead at Tour Championship
-
Kane confirms talks on Bayern extension
-
Maresca salutes 'unbelievable' Cherki after Man City star sinks Palace
-
Trump govt. mulls deal to give away part of Yosemite park
-
Marquinhos rescues last-gasp draw for PSG at Lille in Ligue 1
-
Indian release of Sonia Gandhi memoir uncertain after publisher clarification
-
ICE detains British far-right activist Milo Yiannopoulos in Louisiana
-
Cities show cleaner transport policies can reduce severe air pollution
-
Milo Yiannopoulos held by ICE after missing immigration hearing
-
Four patients harmed in Nashville hospital medication mix-up
-
Six Flags closes X2 rollercoaster after reports of severe brain injuries
-
Essex council hires private guards as Wethersfield asylum centre expands
-
Jury ends second day without verdict in Lindsay Clancy murder trial
-
Haakon VIII becomes Norway's king after Harald V dies at 89
-
Artist says criticised Ronnie O'Sullivan mural is unfinished
-
Six injured after sign falls at Christian festival in West Sussex
-
UAE grants Starlink 10-year satellite broadband licence
-
Dubai airport expands scanners that keep laptops and liquids in bags
-
US says Hormuz mines cleared as diplomacy and military deployments continue
OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal
BELLEVUE, WA / ACCESS Newswire / August 19, 2026 / OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today announced that it has received a written Staff Delisting Determination (the "Determination") from the Nasdaq Listing Qualifications Department notifying the Company that its common stock and warrants are subject to delisting from The Nasdaq Capital Market as a result of the Company's failure to regain compliance with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2).
Nasdaq Hearing Request
The Company intends to request a hearing before the Nasdaq Independent Hearings Panel (the "Panel") to appeal the Staff Determination, pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series. The Company believes it has a compelling case to present to the Panel based on the totality of the circumstances, including OSRH's trading history since listing, the extraordinary market activity observed in OSRH shares on August 17 and 18, 2026 - the two trading days immediately preceding the effective compliance deadline - and the Company's underlying business fundamentals.
On August 17, 2026, OSRH ranked #1 in Most Active Share Volume across all of Nasdaq, with approximately 370 million shares traded. On August 18, 2026, the Company ranked #3, with approximately 145 million shares traded. OSRH's public float is approximately 18.5 million shares meaning the market traded the Company's entire public float more than twenty times over in a single day. The Company's share price reached an intraday high of $0.84 on August 18, sixteen cents from the $1.00 compliance threshold, before declining in the final hours of trading.
The Company believes these market dynamics, and the circumstances that contributed to the compliance shortfall, represent a compelling basis for the Panel's consideration.
"The market spoke with extraordinary conviction on August 17 and 18," said Peter Hwang, Chief Executive Officer of OSR Health. "370 million shares traded in a single day against an 18.5 million share float. We came within sixteen cents of compliance. We are requesting a Panel hearing because we believe the facts support our case, and because our shareholders, who have demonstrated their conviction in this Company so clearly, deserve nothing less than our full effort to fight for continued listing. Whatever the outcome of that process, our commitment to our shareholders does not change."
Important Notice Regarding Trading: Because the Company utilized the second 180-day compliance period under Nasdaq rules, a timely hearing request will not automatically stay the trading suspension. The Company's common stock (OSRH) and warrants (OSRHW) will be suspended from trading on The Nasdaq Capital Market at the opening of business on August 26, 2026. The Company will provide further updates to shareholders regarding the status of its securities as developments warrant. |
About the Staff Determination
The Company was originally notified of its non-compliance with the minimum bid price requirement on September 5, 2025, and was provided an initial 180-calendar-day compliance period through March 4, 2026. On March 5, 2026, the Company received an additional 180-calendar-day compliance period through August 31, 2026. The Staff Determination states that the Company did not regain compliance with the minimum bid price requirement during the applicable compliance period.
The Company intends to request a hearing before the Panel. There can be no assurance that the Panel will grant the Company's request for continued listing or reinstatement of trading.
A copy of this press release is being filed as Exhibit 99.1 to a Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on the date hereof.
About OSR Health, Inc.
OSR Health, Inc. (NASDAQ:OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSR Health engages in immuno-oncology, regenerative biologics, and medical device technologies to improve health outcomes worldwide. Learn more at www.OSR-Health.com.
Investor Contact
OSR Health, Inc.
Investor Relations
[email protected]
Forward-Looking Statements
This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Nasdaq Hearings Panel process and anticipated outcome, the Company's intention to request a hearing before the Panel, the anticipated suspension of trading in the Company's securities, the Company's ability to regain or maintain compliance with Nasdaq's listing requirements, and the Company's business prospects and strategic direction. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially, including the outcome of the Nasdaq appeals process, market conditions, and other risks described in the Company's SEC filings. The Company undertakes no obligation to update any forward-looking statement except as required by law.
SOURCE: OSR Health, Inc.
View the original press release on ACCESS Newswire
B.Finley--AMWN